Skip to main content

Overuse of Antidepressant Drugs for the Treatment of Depression


The problem of under-diagnosis and under-treatment of depression has been identified as a major public health issue and measures have been taken to increase the recognition of depression and its treatment with antidepressants. The possibility of harm from the overuse of antidepressants has attracted far less attention. This review sets out evidence to show that inappropriate use of antidepressants (i.e. outside clinical indications, in excessive doses and for prolonged periods) constitutes a concerning public health problem. Antidepressant prescribing increased by between 4- and 10-fold in various age groups and countries in the last decade of the 20th century. The population of severely depressed patients (in whom antidepressants are accepted to be an effective treatment) who are not receiving antidepressants is probably much smaller than the population receiving these drugs inappropriately. We sound a note of caution for depression awareness campaigns. These apparently well-reasoned responses to the perceived under-recognition of depression can exacerbate over-prescribing. Unless prescribing patterns change, any benefits from increasing access to antidepressants for those with severe depression will be accompanied by significant harms due to inappropriate prescribing in conditions, such as mild depression, where antidepressants are not indicated

This is a preview of subscription content, access via your institution.


  1. 1.

    Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155–7

    PubMed  Article  Google Scholar 

  2. 2.

    Kirsch I, Moore T, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 2002; 5: article 23 [online]. Available from URL: [Accessed 2006 Jul 11]

    Google Scholar 

  3. 3.

    Geddes JR, Freemantle N, Mason J, et al. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 1999; (4): CD001851

    Google Scholar 

  4. 4.

    National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence, 2004

    Google Scholar 

  5. 5.

    Goff VV. Depression: a decade of progress, more to do. NHPF Issue Brief 2002 Nov 22; (786): 1–14

    PubMed  Google Scholar 

  6. 6.

    Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth; a ten year perspective. Arch Pediatr Adolesc Med 2003; 157: 17–25

    PubMed  Article  Google Scholar 

  7. 7.

    Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–12

    PubMed  Article  Google Scholar 

  8. 8.

    Ciuna A, Andretta M, Corbari L, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 2004; 60: 629–34

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002; 2: 111–9

    PubMed  Article  Google Scholar 

  10. 10.

    Rosholm J-U, Gram LF, Isacsson G, et al. Changes in the patter of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 1997; 52: 205–9

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22–7

    PubMed  Article  Google Scholar 

  12. 12.

    Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24: 183–97

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Fergusson D, Doucette S, Cranley Glass K, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396–402

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330(7488): 385–8

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Olfson M, Shaffer D, Marcus S, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82

    PubMed  Google Scholar 

  16. 16.

    Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–72

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    De Leo D, Evans R. International suicide rates and prevention strategies. Washington, DC: Hogrefe & Huber, 2004

    Google Scholar 

  18. 18.

    Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998–2002. Psychatr Serv 2004; 55: 387–91

    Article  Google Scholar 

  19. 19.

    Sparks JA, Duncan BL. The ethics and science of medicating children. Ethical Hum Psychol Psychiatry 2004; 6: 25–39

    PubMed  Google Scholar 

  20. 20.

    De Las Cuevas C, Sanz EJ, De La Fuente JA. Variations in antidepressant prescribing practice: clinical need or market influences? Pharmacoepidemiol Drug Saf 2002; 11: 515–22

    PubMed  Article  Google Scholar 

  21. 21.

    Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004; 42: 1176–85

    PubMed  Article  Google Scholar 

  22. 22.

    Licht R, Qvitzau S, Allerup P, et al. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005; 111: 144–9

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Ellis P, Smith D. Treating depression: the beyondblue guidelines for treating depression in primary care. “Not so much what you do but that you keep doing it”. Med J Aust 2002; 176: S77–83

    PubMed  Google Scholar 

  24. 24.

    Committee on Safety of Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants [online]. Available from URL:, [Accessed 2005 Jul 6]

  25. 25.

    National Collaborating Centre for Mental Health. Depression in children and young people: identification and management in primary, community and secondary care. British Psychological Society, 2005 [online]. Available from URL: [Accessed 2006 May 15]

  26. 26.

    Martinez C, Rietbrock S, Wise L, et al. Anti-depressant treatment on the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389–95

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Elkin I, Gibbons RD, Shea MT, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995; 63: 841–7

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Barrett JE, Williams JR JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18–59 years. J Fam Pract 2001; 50: 405–12

    PubMed  CAS  Google Scholar 

  29. 29.

    Mant A, Rendle V, Hall W, et al. Making new choices about antidepressants in Australia: the long view 1975–2002. Med J Aust 2004; 181: S21–4

    PubMed  Google Scholar 

  30. 30.

    Rushton JL, Clark SJ, Freed GL. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics 2000; 105: 82–7

    Article  Google Scholar 

  31. 31.

    Harrison C, Britt H. The rates and management of psychological problems in Australian general practice. Aust N Z J Psychiatry 2004; 38: 781–8

    PubMed  Article  Google Scholar 

  32. 32.

    Andrews G, Carter GL. What people say about their general practitioners’ treatment of anxiety and depression. Med J Aust 2001; 175: S48–51

    PubMed  Google Scholar 

  33. 33.

    Drug Utilisation Sub-Committee. Australian statistics on medicines 2001–2002. Canberra (ACT): Australian Government, Department of Health and Ageing, 2004

    Google Scholar 

  34. 34.

    Hollinghurst S, Kessler D, Peters T, et al. Opportunity cost of anti-depressant prescribing in England: analysis of routine data. BMJ 2005; 330: 989–1000

    Article  Google Scholar 

  35. 35.

    Andrews G, Sanderson K, Corry J, et al. Using epidemiological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ 2000; 3: 175–86

    PubMed  Article  Google Scholar 

  36. 36.

    Katz SJ, Kessler RC, Lin E, et al. Medication management of depression in the United States and Ontario. J Gen Intern Med 1998; 13: 77–85

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 55–64

    PubMed  Google Scholar 

  38. 38.

    Pomerantz JM, Finkelstein SN, Berndt ER, et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004; 65: 395–404

    PubMed  Article  Google Scholar 

  39. 39.

    Moynihan R, Cassels A. Selling sickness: how drug companies are turning us all into patients. Sydney: Allen & Unwin, 2005

    Google Scholar 

  40. 40.

    Reed E, Vance A, Luk E, et al. Single and combined psychotropic medication use in a child and adolescent mental health service. Aust N Z J Psychiatry 2004; 38: 204–11

    PubMed  Article  Google Scholar 

  41. 41.

    Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder (review). Cochrane Database Syst Rev 2003; (2): CD003592

    PubMed  Google Scholar 

  42. 42.

    Algulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder; twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22

    Article  Google Scholar 

  43. 43.

    Linjakumpu T, Hartikainen S, Klaukka T, et al. Psychotropics among the home-dwelling elderly: increasing trends. Int J Geriatr Psychiatry 2002; 17: 874–83

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Mamdani M, Rapoport M, Shulman Kl, et al. Mental health-related drug utilization among older adults; prevalence, trends and costs. Am J Geratr Psychiatry 2005; 13: 892–900

    Google Scholar 

  45. 45.

    Spore DL, Mor V, Larrat P, et al. Regulatory environment and psychotropic use in board-and-care facilities: results of a 10-state study. J Gerontol A Biol Sci Med Sci 1996; 51: M131–41

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Furniss L, Burns A, Craig SKL, et al. Effects of a pharmacist’s medication review in nursing homes: randomised controlled trial. Br J Psychiatry 2000; 176: 563–7

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Chu L, Schnelle JF, Osterweil D. Prescription analgesic and antidepressant utilization and cost among elderly Medicaid beneficiaries before and after nursing home admission. J Am Med Dir Assoc 2004; 5: 75–81

    PubMed  Article  Google Scholar 

  48. 48.

    Snowdon J, Burgess E, Vaughan R, et al. Use of antidepressants, and the prevalence of depression and cognitive impairment in Sydney nursing homes. Int J Geratric Psychiatry 1996; 11: 599–606

    Article  Google Scholar 

  49. 49.

    Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743–56

    PubMed  CAS  Google Scholar 

  51. 51.

    Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15: 102–10

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum Psychopharma-col 2003; 18: 185–90

    Article  CAS  Google Scholar 

  53. 53.

    Jureidini J, Doecke C, Mansfield P, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879–83

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Brent D. Antidepressants and pediatric depression: the risk of doing nothing. N Engl J Med 2004; 351: 1598–601

    PubMed  Article  CAS  Google Scholar 

  55. 55.

    Tonkin A, Jureidini J. Wishful thinking: antidepressant drugs in childhood depression. Br J Psychiatry 2005; 187: 304–5

    PubMed  Article  Google Scholar 

  56. 56.

    Lyons JS, MacIntyre JC, Lee ME, et al. Psychotropic medications prescribing patterns for children and adolescents in New York’s public mental health system. Community Ment Health J 2004; 40: 101–18

    PubMed  Article  Google Scholar 

  57. 57.

    National Collaborating Centre for Mental Health. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and British Psychological Society, 2003

    Google Scholar 

  58. 58.

    Gilberg K, Laouri S, Wade S, et al. Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression and CHF. J Managed Care Pharm 2003; 3: 232–7

    Google Scholar 

  59. 59.

    Tierney R, Melfi CA, Signa W, et al. Antidepressant use and use patterns in naturalistic settings. Drug Benefit Trends 2000; 6: 7–12

    Google Scholar 

  60. 60.

    Healy D, Aldred G. Anti-depressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163–72

    PubMed  Article  Google Scholar 

  61. 61.

    Kessler R, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289: 3095–105

    PubMed  Article  Google Scholar 

  62. 62.

    Spijker J, deGraaf R, Bijl R, et al. Duration of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208–13

    PubMed  Article  Google Scholar 

  63. 63.

    Thomson O’Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; (2): CD000409

    Google Scholar 

Download references


Ralph Faggotter and Brita Pekarsky contributed ideas to this paper. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest relevant to the content of this review.

Author information



Corresponding author

Correspondence to Jon Jureidini.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jureidini, J., Tonkin, A. Overuse of Antidepressant Drugs for the Treatment of Depression. CNS Drugs 20, 623–632 (2006).

Download citation


  • Nursing Home
  • Paroxetine
  • Eating Disorder
  • Venlafaxine
  • Suicide Rate